ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
Dow Jones
44,296.51
0.97%
US Dollar vs MXN
20.4284
0.00%
Brent Oil
74.65
0.00%
Bitcoin
98,609.50
-0.43%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Europa
  5. EU

  6. Celyad Oncology SA (CYAD) Cotización

Celyad Oncology SA

Celyad Oncology SA (CYAD)

EU
0.651
0.001
(0.15%)
Cerrado 23 Noviembre 10:30AM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
0.651
Postura de Compra
0.65
Postura de Venta
0.678
Volume Operado de la Acción
13,925
0.651 Rango del Día 0.68
0.212 Rango de 52 semanas 1.22
Capitalización de Mercado [m]
26.97M
Precio Anterior
0.65
Precio de Apertura
0.68
Hora
50
@
0.651
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
77,289
Acciones en circulación
41,429,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-3.19
Beneficio por acción (BPA)
-0.2
turnover
102k
Beneficio neto
-8.45M

Acerca de Celyad Oncology SA

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.celyad.com
Sede
Mont-saint-guibert, Walloon Brabant, Bel
Fundado
-
Celyad Oncology SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker CYAD. The last closing price for Celyad Oncology was 0.65 €. Over the last year, Celyad Oncology shares have traded in a share price range of 0.212 € to 1.22 €.

Celyad Oncology currently has 41,429,000 shares in issue. The market capitalisation of Celyad Oncology is 26.93 € million. Celyad Oncology has a price to earnings ratio (PE ratio) of -3.19.

CYAD Últimas noticias

Más noticias

Celyad Oncology Présentera au Congrès Annuel SITC 2024

Regulatory News: Celyad Oncology (Euronext: CYAD) (la “Société”), annonce aujourd'hui la présentation de deux posters lors de la 39e réunion annuelle de la Society for Immunotherapy of Cancer...

07 Octubre 2024
Business Wire

Celyad Oncology announces intention to terminate SEC reporting obligations

MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with...

08 Febrero 2024
GlobeNewswire Inc.

Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...

16 Enero 2024
GlobeNewswire Inc.

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces, in accordance with Article 14 of the...

20 Diciembre 2023
GlobeNewswire Inc.

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK...

15 Diciembre 2023
GlobeNewswire Inc.

Celyad announces management change

MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD), a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of...

04 Diciembre 2023
GlobeNewswire Inc.

Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2023 (GLOBE NEWSWIRE) -- regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance...

01 Diciembre 2023
GlobeNewswire Inc.

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the...

21 Noviembre 2023
GlobeNewswire Inc.

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the...

14 Noviembre 2023
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.21147.95454545450.440.8350.435917920.67733363DE
40.381141.1111111110.271.220.261898850.75005438DE
120.391150.3846153850.261.220.2205772890.66743937DE
260.332104.075235110.3191.220.212430830.5962772DE
520.13325.67567567570.5181.220.212375190.50926738DE
156-2.794-81.10304789553.4454.60.212402501.38998331DE
260-10.769-94.29947460611.4212.080.212426653.86980209DE

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MLAAHAmatheon Agri Holding NV
0.02 €
(100.00%)
5k
GNROGeNeuro SA
0.0768 €
(25.49%)
200
BIDSGascogne DS
0.005 €
(25.00%)
150.51k
ALSAFSAFE
0.11 €
(23.73%)
39.98k
ALKKOKKO International SA
0.112 €
(21.21%)
4.13M
ALIMOGroupimo
0.189 €
(-40.94%)
392
MLUMGUmalis Group
1.30 €
(-31.22%)
1.71k
MLNMAMiguet Et Associes
0.075 €
(-24.62%)
1.72k
MLSEQSequa Petroleum NV
0.008 €
(-20.00%)
23k
VACBSPierre & Vacances
0.05 €
(-15.25%)
35.99k
BCPBanco Comercial Portugues SA
0.4446 €
(-0.49%)
69.24M
ALNEVNeovacs
0.0002 €
(0.00%)
41.4M
ALCYBCybergun
0.0001 €
(0.00%)
30.32M
INGAING Groep NV
14.652 €
(-1.16%)
14.06M
ACACredit Agricole SA
13.05 €
(-1.66%)
8.06M

Discusión

Ver feed completo
caycehopeful caycehopeful 6 minutos hace
Q quarterly--I'm sure Big D still has some surprises for Josh and Angus!..............not the good kind.
https://www.otcmarkets.com/otcapi/company/financial-report/417479/content
ATWT
Steady_T Steady_T 9 minutos hace
That embedding worked for me. My Pillow guy for head inquisitor at Gitmo. Play My pillow commercials 24/7 till they break. No need for waterboarding.
in99flyers in99flyers 10 minutos hace
Shiba has outperformed both XRP and ADA on the 1 year chart. Stop being a prisoner of the moment and relax and know what you own
SHIBUSD
Jack Torrance Jack Torrance 12 minutos hace
Yeah, the comparison to the dotcom bubble is so stupid. This is a real company with real, actual, groundbreaking technology. And they are under-promising and over-delivering, which is so rare and refreshing for start ups these days.
IONQ
Steady_T Steady_T 13 minutos hace
Where did you get that silly idea?
kittycattttt kittycattttt 13 minutos hace
:-)
DOGEUSD
Researchfyi Researchfyi 15 minutos hace
Does this raise more questions…

https://www.investopedia.com/terms/s/sec-form-s-1.asp
LQMT
Preciouslife1 Preciouslife1 15 minutos hace
https://www.facebook.com/share/r/1AqQRy2Hdm/?mibextid=6GsUZ4
BubbaInSC BubbaInSC 18 minutos hace
FUNN not so Fun

Wow. Guess I’m not surprised at downturn.

End of year selling for tax write off of losses.

For those who have money to lose, maybe someone can pick up stock in 0.001s
FUNN
jason sundar jason sundar 22 minutos hace
Another up day with volume 
BARUF
HyGro HyGro 23 minutos hace
Clearly NOT. NWBO gets paid for patients on com[passionate care programs. Advent's rate card for DCVax-L compassionate care is $250K. And NWBO has not shown any material revenue so clearly they are not treating many patients as all -- whether UK or U.S.

Once again, you seem to ig
NWBO
johnydollar johnydollar 24 minutos hace
They probably read 📚 them as they sh!t bricks.........

It's not fun to sh!t bricks.........

Oh do they miss revocation........

Oh well........

😆 🤣 😂 😹 😆 🤣 😂 😹 😆
DBMM
littlejohn littlejohn 24 minutos hace
SMCI may start trying on $38 on Monday...

that is steady resistance going back to

being set up as support back in early

September on lows on trading days...

https://www.barchart.com/stocks/quotes/SMCI/interactive-chart

Buyers
SMCI
Researchfyi Researchfyi 26 minutos hace
Great post! Great find!

Now I have to read.
And the sad part….its a dice roll under a nickel with enough material comparable to a mega cap.

Who the heck put a fire under IB’s and TC’s seat?
LQMT
DiamondHealer95 DiamondHealer95 29 minutos hace
Yes, and I posted 2 hours before you asked this. Ben provided the delay information.

Nobody pays attention to my posts, they choose to believe their own fantasies or the embellished posts.

The date i said after the conference was announced would have been correct if n
KBLB
Zorax Zorax 29 minutos hace
I would do 2 or 3. I don't see any reason to dismiss, and me, I don't see any reason why he didn't get sentenced last year.
Researchfyi Researchfyi 34 minutos hace
Thank you TC,

Guess that question was answered…

Researchfyi
Re: None
Tuesday, 11/19/2024 1:44:38 AM
I raised this question before. I always thought LL paid $63 million for 405 million common unrestricted shares per each PR and filled documents. Ho
LQMT
MrLourdes MrLourdes 37 minutos hace
Netlist Inc. Triumphs in Landmark Samsung Trial with $118 Million Jury Award
Feel Free To Share
https://www.linkedin.com/pulse/netlist-inc-triumphs-landmark-samsung-trial-118-million-gary-wallach-1lmlc/?trackingId=X6%2Bg3TQB%2FxRh8tZPFQ5Jcw%3D%3D

NLST
Moonboy1 Moonboy1 37 minutos hace
Does not dies
SHIBUSD
Moonboy1 Moonboy1 37 minutos hace
This will run eventually and when it dies it will be epic. The hardest part is picking which coun will the most at any given time. It's hard watching xrp, cardano, etc. Running massively with money tied up here. But the longer they hold it back the more explosive the run will be. I just like spewing
SHIBUSD
Seminole Red Seminole Red 38 minutos hace
another group that needs fired for their beliefs......FEMA

At Hearing On Fired FEMA Staffer Skipping Trump Houses Raskin Notes Workers Felt ‘Unsafe’ In Trump Areas

https://www.msn.com/en-us/news/us/at-hearing-on-fired-fema-staffer-skipping-trump-houses-raskin-notes-work
Echo115 Echo115 38 minutos hace
WITH ITS NEW PRODUCT LINE TRICASCADE IS FINALLY BEGINNING TO SHOW SOME PROMISE FOR INVESTORS.

THEIR VOS 5G DONGLE SALES ARE IMPROVING…THEIR NEW GS500G IoT 5G MODEM IS LIKELY TO BECOME A HOT SELLER TO BUSINESSES AND THEIR NEW E-BIKE IS DUE TO BE UNVEILED IN JANUARY IN LAS VEGAS..
SRMX
arizona1 arizona1 41 minutos hace
Biden still has time to fire Garland and forever put him to shame. The POS actually appointed a Special Counsel for his son, Hunter, who never worked in government, was a private citizen and had drug and tax problems like every MAGAt that ever lived.

That Biden didn't protect his
rosemountbomber rosemountbomber 43 minutos hace
Thanks Capt. I guess to some degree it doesn't matter much since V is an approved drug and so forth. Not sure how much micro managing the head of the FDA would get involved in when it comes to the new formulation. I guess they have set rules they follow.

I find it interesting in a
AMRN

Su Consulta Reciente

EU
CYAD
Celyad Oncology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados